

This requisition form can be used to submit an order for the **Long-Chain Fatty Acid Oxidation Disorders Program**, a sponsored testing program for genetic disorders brought to you by **Ultragenyx Pharmaceutical Inc.** and **Invitae Corporation**.

**INSTRUCTIONS:** Review the ordering options and then complete all sections of this form. Your ordering option will be indicated in the test selection section.

### ORDERING OPTIONS

#### 1. LONG-CHAIN FATTY ACID OXIDATION DISORDERS PROGRAM

For individuals that meet the eligibility criteria below and wish to receive the program specific genetic testing panels.

**REQUIRED: You must select below the appropriate eligibility criteria for this patient.**

**This program is available to patients in the US and Canada who meet at least one of the following criteria:**

- The patient has completed the UltraCare Start Form for LC-FAOD (If available, please provide a copy of abnormal biochemical confirmatory labs)
- OR**
- Patient is suspected of having, or has been diagnosed with a long-chain fatty acid oxidation disorder (**check at least one**) **AND** a plasma acylcarnitine test has either been performed (regardless of result - abnormal or normal) or has been ordered.
- Carnitine palmitoyltransferase (CPT) IA deficiency
- Carnitine-acylcarnitine translocase (CACT) deficiency/  
Carnitine palmitoyltransferase (CPT) II deficiency
- Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency/Mitochondrial trifunctional protein (TFP) deficiency
- Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency

#### 2. GENE-SPECIFIC FAMILY FOLLOW-UP TESTING

For relatives of program participants who received a Pathogenic/Likely Pathogenic result or approved VUS who want to receive gene specific family follow-up testing at no additional cost. Relatives do not need to meet the eligibility criteria listed above. Learn more at [www.invitae.com/family](http://www.invitae.com/family).

#### PATIENT INFORMATION

First name	MI	Last name
Date of birth (MM/DD/YYYY)	Biological sex <input type="radio"/> M <input type="radio"/> F	MRN (medical record number)
Ancestry <input type="radio"/> Asian <input type="radio"/> Black/African American <input type="radio"/> White/Caucasian <input type="radio"/> Ashkenazi Jewish <input type="radio"/> Hispanic <input type="radio"/> Native American <input type="radio"/> Pacific Islander <input type="radio"/> French Canadian <input type="radio"/> Sephardic Jewish <input type="radio"/> Mediterranean <input type="radio"/> Other: _____		
Phone	Email address (report access after clinician releases)	
Address		City
State/Prov	ZIP/Postal code	Country
<b>Ship a saliva kit to this patient</b> (to submit, fax this form to Client Services at 415-276-4164) <input type="radio"/> Ship kit to address above <input type="radio"/> Ship kit to alternate address: _____		

#### SPECIMEN INFORMATION

**Specimen type:** Blood (3-mL purple EDTA) **-OR-** Saliva (Oragene™) **-OR-** Assisted Saliva **-OR-** DNA source: \_\_\_\_\_

*We are unable to accept blood/saliva from patients with:*  
 • *Allogeneic bone marrow transplants* • *Blood transfusion <2 weeks prior to specimen collection*

**Specimen collection date (MM/DD/YYYY):**     
*If not provided, the day before specimen receipt will be used*

**Special cases:**  History of/current hematologic malignancy in patient

INVITAE PARTNER CODE **FAOD**

#### CLINICIAN INFORMATION

Organization name		
Phone	Fax	
Address		City
State/Prov	ZIP/Postal code	Country
<b>Primary clinical contact name</b> (if different from ordering provider)		NPI
Primary clinical contact email address (for report access)		
<b>Ordering provider (select one ordering provider by marking the checkbox before the name)</b>		
<input type="checkbox"/>	Name	NPI
<input type="checkbox"/>	Email address (for report access)	
<input type="checkbox"/>	_____	
<input type="checkbox"/>	_____	
<input type="checkbox"/>	_____	
<input type="checkbox"/>	_____	
<input type="checkbox"/>	_____	
<b>Additional clinical or laboratory contacts (optional, to share access to order online)</b>		
<input type="radio"/>	Share this order with the primary clinical contact's default clinical team, manage at <a href="http://invitae.com">invitae.com</a>	
<input type="checkbox"/>	Name	Email address (for report access)
<input type="checkbox"/>	Name	Email address (for report access)

**CLINICAL HISTORY**
**FAMILY HISTORY**

Is there a family history of disease for which the patient is being tested?  Yes  No If yes, describe below and attach pedigree and/or clinical notes.

Relative's relationship to this patient	Maternal or paternal	Diagnosed condition	Age at diagnosis	Relative's relationship to this patient	Maternal or paternal	Diagnosed condition	Age at diagnosis

**PERSONAL HISTORY**

Is/was this patient affected or symptomatic?†  Yes  No  
Provide details in the required clinical history questions (if applicable).

† Symptomatic means this patient has features or signs known or suspected to be related to the genetic testing being ordered and could include findings on physical examination, laboratory tests, or imaging.

**REQUIRED CLINICAL HISTORY**
**Outcome of Newborn Screen (NBS)**

- Positive – Suspected disorder \_\_\_\_\_  
 Negative  
 Unknown

**Please provide a copy of the plasma acylcarnitine results.** Providing a copy of plasma acylcarnitines results, or any other confirmatory tests, when available, is strongly encouraged. These results are helpful for variant interpretation and in some cases can make a difference for the final interpretation of the variant.

- Plasma acylcarnitine or confirmatory results attached  
 Test results unavailable

**Outcome of confirmatory testing (e.g. acylcarnitine test)**

- Positive – Disorder \_\_\_\_\_  
 Inconclusive – Disorder(s) \_\_\_\_\_  
 Negative

**What prompted you to suspect this patient may have a long-chain fatty acid oxidation disorder?** (Exclude PHI)

**If confirmatory test was positive, what is the reason for conducting this genetic test?** (check all that apply)

- Payer requirement  
 Differential diagnosis (between LC-FAOD types)  
 Distinguish affected versus carrier status  
 Understand disease course/prognosis  
 Inform treatment decision  
 Genetic counseling  
 Identify at-risk family members  
 Research  
 Other \_\_\_\_\_

**Ongoing clinical features:** (check all that apply)

- |  |   |
|--|---|
| <input type="radio"/> Cardiomyopathy             | <input type="radio"/> Myoglobinuria         |
| <input type="radio"/> Elevated creatinine kinase | <input type="radio"/> Peripheral neuropathy |
| <input type="radio"/> Hepatomegaly               | <input type="radio"/> Reye like syndrome    |
| <input type="radio"/> Hypoketotic hypoglycemia   | <input type="radio"/> Rhabdomyolysis        |
| <input type="radio"/> Liver failure              | <input type="radio"/> Retinitis pigmentosa  |
| <input type="radio"/> Muscle myopathy            | <input type="radio"/> Other _____           |

**OPTIONAL - REQUESTED VARIANTS FOR THIS PATIENT'S REPORT, IF KNOWN**

To have the presence or absence of specific variants commented on in this patient's report, provide the details below. For gene-specific family follow-up see **Note** under Test Selection.

Was the proband (individual with variant) tested at Invitae?  Yes, Invitae Order ID: RQ# \_\_\_\_\_  No: Attach copy of lab results (required)

Variant(s) (e.g. GENE c.2200A>T (p.Thr734Ser) NM\_00012345) If left blank, all variants identified in the proband will be commented on.

This patient's relationship to proband:

- Parent  Sibling  Grandchild  
 Child  Self  Other: \_\_\_\_\_

**TEST SELECTION – Select option 1 or 2 below:**
 **1. LONG-CHAIN FATTY ACID OXIDATIONS DISORDERS PROGRAM – Indicate test(s) to be performed below:**

Test code	Test name	# of genes	Gene list
<input checked="" type="radio"/> 06165	Invitae Fatty Acid Oxidation Defects Panel	17	ACADM, ACADS, ACADSB, ACADVL, CPT1A, CPT2, ETFA, ETFB, ETFDH, HADH, HADHA, HADHB, HMGCL, HMGCS2, MLYCD, SLC22A5, SLC25A20
<input type="radio"/> 06165.1	Add-on 4-Dienoyl-CoA reductase deficiency	1	NADK2
<input type="radio"/> 06165.2	Add-on Riboflavin transporter deficiency	3	SLC52A1, SLC52A2, SLC52A3

 **2. GENE-SPECIFIC FAMILY FOLLOW-UP TESTING** *For relatives of a program participant ('proband') who received a Pathogenic/Likely Pathogenic result or approved VUS.*

<b>Proband's Invitae Order ID:</b> RQ# _____	<b>This patient's relationship to proband:</b> <input type="radio"/> Parent <input type="radio"/> Sibling <input type="radio"/> Grandchild <input type="radio"/> Child <input type="radio"/> Other: _____	<b>Gene(s) to be tested in this patient:</b>
---	---	--

**NOTE:** The presence or absence of all variants identified in the proband for the gene(s) ordered for gene-specific family follow-up will be commented on in this patient's report unless a limited selection is specified in the **Requested Variants** section above. Invitae will report any Pathogenic/Likely Pathogenic variants found in this patient for the gene(s) ordered.

Invitae continually updates its panels based on the most recent evidence. If an order is placed using an outdated test requisition form, Invitae reserves the right to upgrade ordered tests to their current versions. Test IDs containing add-on codes will include the original panel as well as the add-on.

By signing this form, the medical professional acknowledges that the individual/family member authorized to make decisions for the individual (collectively, the "Patient") has been supplied information regarding and consented to undergo genetic testing, substantially as set forth in Invitae's Informed Consent for Genetic Testing ([www.invitae.com/forms](http://www.invitae.com/forms)). In connection with the Program the Patient has been informed that Invitae may notify them of clinical updates related to genetic test results (in consultation with the ordering medical professional as indicated) and has been informed that deidentified Patient data may be used and shared with third parties, for research and commercial purposes and, in the U.S., to contact their medical professional. For orders originating in Canada, the Patient has been informed that their personal information and specimen will be transferred to and processed in the U.S. and that de-identified Patient data may be used and shared for research and commercial purposes in the U.S. The medical professional warrants that he/she will not seek reimbursement for this no-charge test from any third party, including but not limited to federal healthcare programs. The medical professional also hereby acknowledges that organization and clinician contact information provided in the order may be shared with third parties, including commercial organizations, that may contact the medical professional directly in connection with the Program, and that they have made the Patient aware that de-identified Patient data may be used and shared with such third parties, for purposes which include contacting their medical professional directly in connection with the Program. A list of third party partners may be provided upon request. I attest that I am authorized under applicable state law to order this test.

<b>Medical professional signature (required)</b>	<b>Date (MM/DD/YYYY)</b>
--	--------------------------